We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Actavis, Inc. | NYSE:WPI | NYSE | Ordinary Share |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 85.73 | 0.00 | 01:00:00 |
From May 2019 to May 2024
Mylan Inc. (MYL) has launched a generic version of Pfizer Inc.'s (PFE) blockbuster cholesterol Lipitor after receiving approval from the U.S. Food and Drug Administration.
The generic drug-maker will market the widely-prescribed drug as Atorvastatin Calcium Tablets, in 10 miligrams, 20 miligrams, 40 miligrams and 80 miligrams.
Lipitor had U.S. sales of $8.1 billion for the 12 months ended March 31, the company said, citing IMS Health.
Mylan has seen its top line grow in recent quarters as a shaky economy drove customers to low-cost health options, though litigation and restructuring costs have pressured earnings. The company has 171 abbreviated new drug applications pending with U.S. regulators, representing $84 billion in annual sales.
Pfizer, by contrast, has seen its earnings slump 19% in the first full quarter since losing market exclusivity on Lipitor last year. Watson Pharmaceuticals Inc. (WPI) is also selling a generic version of the drug.
Mylan shares were up 19 cents to $21.82 in recent trading. The stock is up 1.7% so far this year.
-By Kristin Jones, Dow Jones Newswires; 212-416-2208; kristin.jones@dowjones.com
1 Year Watson Chart |
1 Month Watson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
